DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 2,565 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the transaction, the executive vice president owned 126,043 shares in the company, valued at $11,138,419.91. This trade represents a 1.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 1.7%

NASDAQ:DXCM opened at $90.82 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm’s fifty day moving average is $79.21 and its 200-day moving average is $71.60. The firm has a market cap of $34.27 billion, a P/E ratio of 35.90, a P/E/G ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 earnings per share. Equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. UBS Group set a $96.00 target price on DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Argus increased their price target on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

Institutional Trading of DexCom

Several hedge funds have recently bought and sold shares of DXCM. MassMutual Private Wealth & Trust FSB raised its holdings in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares in the last quarter. Essex Financial Services Inc. grew its holdings in shares of DexCom by 5.7% during the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the last quarter. Keel Point LLC grew its holdings in shares of DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after buying an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.